Intercept Pharmaceuticals Inc % de acciones cortas

¿Qué es el % de acciones cortas de Intercept Pharmaceuticals Inc?

El % de acciones cortas de Intercept Pharmaceuticals Inc es 12.40%

¿Cuál es la definición de % de acciones cortas?



El porcentaje corto de flotación es la cantidad de acciones en corto en comparación con la flotación expresada como un porcentaje.

Short percentage of float, or short interest ratio, is calculated by taking the total amount of shares shorted and dividing it by the total amount of shares available for trade. It is an indirect metric of investor sentiment. When short percentage of float is high, above 40%, it implies company investors hope shares will decline in value. The percentage is used by both fundamental and technical traders to identify trends. The short percentage of float can also be calculated for entire exchanges to determine the sentiment of the market as a whole. If it is high of around five or greater for an exchange, this can be taken as a bearish signal, and vice versa.

% de acciones cortas de compañías en Sector Health Care en NASDAQ en comparadas con Intercept Pharmaceuticals Inc

¿Qué hace Intercept Pharmaceuticals Inc?

we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.

Empresas con % de acciones cortas similar a Intercept Pharmaceuticals Inc